Over the next quarter-century, the number of people living with type 1 diabetes is expected to grow from 9.4 million to 12.1 million worldwide — a rise shaped not only by biology and aging populations in wealthy nations, but by the slow, uneven spread of insulin access to places where survival itself has long been uncertain. Researchers at Steno Diabetes Center Odense have modeled this trajectory using historical patterns of care and population data, presenting their findings at the European Association for the Study of Diabetes meeting in Milan this autumn. The projection is, in one sense, a
News-Medical
· Aug 29, 2026
· health
· 4 min read
High
Sourcing: Verified
Type 1 diabetes cases projected to surge 29% globally by 2049
Mortality among T1D patients projected to increase from 361,383 deaths in 2025 to 537,621 in 2049, with children aged 0-19 accounting for disproportionate mortality in low-income countries.
◉
Science & Space
7802 related articles
NASA Launches Artemis II: Four Astronauts Head to Moon in Historic Mis…
Devdiscourse · 100% match
Artemis III Core Rocket Stage Arrives at Kennedy for Late 2027 Launch
Google News · 99% match
SpaceX launches tissue chips and organoids to ISS for groundbreaking s…
Space.com · 99% match
SpaceX Dragon carries Moon microscope, solar arrays and space tomatoes…
The Indian Express · 99% match
SpaceX Dragon delivers 5,000 lbs of science cargo to ISS in 33rd resup…
Phys.org · 99% match
Related Coverage
The Guardian · Sep 10
North Korea builds new uranium enrichment facility at Yongbyon, IAEA warns
The IAEA reports North Korea has built a new uranium enrichment facility at Yongbyon capable of producing weapons-grade …
News-Medical · Sep 10 Bruker, Translucence Partner to Streamline 3D Tissue Imaging WorkflowsBruker Corporation and Translucence Biosystems announced a collaboration combining tissue-clearing solutions with light-…
ABC News & Headlines – Australian Broadcasting Corporation · Sep 10 Rare Denisovan fossils and tools unearthed in Chinese cave offer new insights into extinct cousinsArchaeologists uncovered seven Denisovan fossils alongside thousands of tools and bone fragments in a Chinese cave, offe…
Space · Sep 10 SpaceX launches classified Space Force mission USSF-153 from CaliforniaSpaceX is launching a classified USSF-153 mission for the U.S. Space Force from Vandenberg Space Force Base on September…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
Type 1 diabetes cases projected to increase 29% globally by 2049, with fastest growth in low-income countries as healthcare access improves, creating disparities in disease burden.
Escalation Risk
low
Confidence
HIGH
Global
Low-income countries (Tanzania, sub-Saharan Africa)
High-income countries (USA, UK, Italy, Australia)
Middle-income countries
Healthcare infrastructure disparities will widen; high-income nations maintain diagnostic advantage and treatment capacity, while low-income countries face surging cases with limited insulin access and healthcare systems. This reinforces existing global health inequities and may shift pharmaceutical market dynamics toward emerging markets.
Similar to HIV/AIDS epidemiology patterns where disease burden shifted toward resource-limited settings; reflects broader trend of non-communicable disease globalization affecting developing nations disproportionately.
Economic Lens
📈
Type 1 diabetes cases projected to increase 29% globally by 2049, driving demand for insulin, healthcare services, and diabetes management products across pharmaceutical and medical device sectors.
Market Signal
bullish
Confidence
MED
Pharmaceutical (insulin manufacturers)
Medical devices (glucose monitors, pumps)
Healthcare services and diagnostics
Health insurance
Biotechnology
Public health systems
Households will face increased healthcare costs for insulin, monitoring devices, and ongoing treatment. Low-income countries may experience affordability challenges despite improved access. High-income countries will see higher insurance premiums and out-of-pocket expenses as prevalence rises.
Governments will need to expand insulin procurement and distribution infrastructure, particularly in low-income countries. Regulatory bodies may implement price controls on insulin and diabetes management products. Public health systems will require increased funding for diabetes screening, prevention programs, and long-term care management.